SEATTLE, Feb. 5, 2018 /PRNewswire/ -- LumiThera, a clinical stage medical device company focused on developing photobiomodulation(PBM) therapies for ocular disorders and disease, today announced that it will participate in the 7th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 9, 2018 at The Palace Hotel, in
Thomas M. Brunner, President and CEO of Glaucoma Research Foundation, said "This unique full-day meeting unites medicine, research, and industry, in order to advance new and promising developments in the treatment of glaucoma."
Clark E. Tedford, CEO of LumiThera, said, "We are delighted to be presenting at this highly respected Glaucoma conference. We believe our presentation will provide researchers, physicians and investors with a snapshot of LumiThera's clinical development of a novel PBM treatment for dry age-related macular degeneration, and PBM's potential use in other degenerative eye diseases."
Glaucoma 360 was founded by Adrienne Graves, PhD, and Andrew Iwach, MD, who serve on the Glaucoma Research Foundation Board of Directors. Drs. Graves and Iwach also serve as Co-Chairs for the Glaucoma 360 New Horizons Forum. Dr. Iwach, GRF Board Chair and Executive Director at the Glaucoma Center of San Francisco, said, "Glaucoma 360 is designed to bring greater awareness to unmet medical needs in glaucoma and to highlight current and novel therapies that will help preserve sight for patients with glaucoma." Dr. Graves, noted, "Since our inaugural meeting in 2012, we have highlighted more than 70 presenting companies and technologies." For more information on Glaucoma 360, visit www.glaucoma360.org.
About Glaucoma Research Foundation Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit organization dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $60 million to advance essential research and education programs.
About LumiThera Inc.LumiThera is a clinical-stage medical device company focused on treating people affected by ocular disorders and diseases including dry age-related macular degeneration. The Company is a leader in the use of photobiomodulation using light emitting diodes ("LED") for treatment of acute and chronic ocular diseases and disorders. The Company is developing the LED office-based LT-300 instrument to be used by ophthalmologists and other eye specialists as non-invasive medical treatments.
For more information, please contact:
2018 LumiThera Inc., All rights reserved.
View original content:http://www.prnewswire.com/news-releases/lumithera-inc-to-participate-in-the-2018-glaucoma-360-in-san-francisco-300593198.html
SOURCE LumiThera Inc.
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All